Tzvetan Tzvetanov
Internal Medicine · North Andover, MANPI 1417938069
Payments from drug & device makers
Across 143 payments — averaging $16.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tolmar, Inc.$533
- Johnson & Johnson$355
- AstraZeneca$261
- Otsuka America Pharmaceutical, Inc.$234
- Boehringer Ingelheim$205
- AbbVie$157
- plus $630 from 17 others
What the payments were for
- Food & beverage$2,32998%
- Education$472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tolmar, Inc. | 57 | $533 |
| Johnson & Johnson | 19 | $355 |
| AstraZeneca | 12 | $261 |
| Otsuka America Pharmaceutical, Inc. | 4 | $234 |
| Boehringer Ingelheim | 9 | $205 |
| AbbVie | 9 | $157 |
| Exact Sciences | 4 | $91 |
| Antares Pharma, Inc. | 4 | $80 |
| Pfizer | 4 | $79 |
| Novo Nordisk | 4 | $72 |
| Idorsia Pharmaceuticals US Inc | 2 | $42 |
| Novartis | 2 | $33 |
| Lucid Diagnostics Inc. | 2 | $32 |
| Ultragenyx Pharmaceutical Inc. | 2 | $31 |
| Boston Scientific | 1 | $23 |
| Lundbeck LLC | 1 | $22 |
| Philips North America LLC | 1 | $21 |
| Scpharmaceuticals Inc. | 1 | $21 |
| Biogen | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Tempus AI, Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$103
How this compares
$2,376 in reported general payments places this provider in the 85th percentile of 4,983 internal medicine providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 30 | $36,213 |
| EliquisApixaban | 12 | $16,630 |
| OzempicSemaglutide | 12 | $9,954 |
| Colchicine | 23 | $2,230 |
| Atorvastatin Calcium | 89 | $1,404 |
| Rosuvastatin Calcium | 69 | $1,115 |
| Testosterone | 11 | $825 |
| Losartan Potassium | 41 | $676 |
| Celecoxib | 41 | $639 |
| Metoprolol Succinate | 27 | $592 |
| Gabapentin | 47 | $518 |
| Metformin Hcl ErMetformin Hcl | 41 | $482 |
| Levothyroxine Sodium | 67 | $444 |
| Diclofenac Sodium | 16 | $372 |
| Allopurinol | 14 | $365 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $17 | $36,21330 claims |
| PfizerEliquis | $79 | $16,63012 claims |
| Novo NordiskOzempic | $72 | $9,95412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,983 internal medicine providers in Massachusetts.
Other internal medicine in North Andover
- Noopur RajeBoston$19.9M
- Michael McCartneyNewburyport$17.6M
- Rebecca HeistBoston$17.4M
- Richard PlattBoston$13.5M
- Ryan CorcoranBoston$11.4M
- Joyce LiuCharlestown$10.3M
- Elizabeth LeeBoston$9.8M
- Adnan DahdulSpringfield$8.8M
- Ryan SullivanCambridge$8.5M
- Xiuning leBoston$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.